The United States of America As Represented by the Department of Health

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Other

The United States of America As Represented by the Secretary of

Celgene Corporation

Genetics Institute, Inc.

Robert Yarchoan

Samuel Broder

Giovanna Tosato

Hiroaki Mitsuya

Matthew L Sherman

Gene M Shearer

Richard S Little

Jill Lietzau

Kathleen Wyvill

James M Pluda

Ellen Feigal

Jerome B Zeldis

Jay A Berzofsky

Warren Jaye Leonard

Vikram Khetani

Takahiro Okazaki

Warner C Greene

David A Nelson

Thomas S Uldrick

Denise Whitby

Mark N Polizzotto

Andrew Catanzaro

James T Snyder, Ii

M Wayne Saville

David A Davis

Kazuyuki Taga

Laurence Rubin

William Biddison

Irini Sereti

David Davis

Thomas Uldrick

Mark Polizzotto

Provided herein are uses of gene and protein biomarkers as a predictor of clinical sensitivity of Kaposi's sarcoma (KS) or Kaposi's sarcoma-associated herpesvirus (KSHV) induced lymphoma and patient response to treatment with an immunomodulatory compound. Further provided herein are methods for the treatment or management of Kaposi's sarcoma or KSHV-induced lymphoma with an immunomodulatory compound, alone or in combination with doxorubicin.

Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers

The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.

Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus

Methods are provided for using IL-12 to treat Kaposi's sarcoma (KS), particularly AIDS-associated KS.

Treatment of Kaposi's sarcoma with IL-12

The present invention provides a method of inhibiting the replication of human immunodeficiency virus in cells which are infected with HIV comprising administering to the cells a replication inhibiting amount of interleukin-10. Also provided is a parenteral method of the administration of interleukin-10 administration. Further provided is a method of inhibiting retroviral replication in a human subject infected by a retrovirus, comprising administering to the subject an inhibiting amount of interleukin-10, including the retrovirus is. Finally, a method of treating Kaposi's sarcoma in a human subject comprising administering to the subject an effective amount of interleukin-10 to the subject is provided.

Methods of inhibiting viral replication using IL-10

A method for inhibiting intracellular replication of HIV in an HIV-infected individual comprising contacting the HIV reverse transcriptase in the HIV-infected cells with 2',3'-dideoxyadenosine-5'-triphosphate whose source is 2',3'-dideoxyadenosine or a pharmaceutically acceptable salt or prodrug thereof.

Method of inhibiting HIV replication with 2',3'-dideoxyadenosine

A preferred method and dosages for treatment of retrovirus-induced dementia by the administration of 2',3'-dideoxyinosine(ddI) is disclosed.

Treatment of retroviral induced dementia by administration of

A preferred method and dosages for the short and long-term treatment of human retroviral infections, or retroviral-like infections, including acquired immunodeficiency syndrome (AIDS) and other manifestations of human immunodeficiency virus (HIV) infection, with 2',3'-dideoxyinosine (ddl) are disclosed, along with a protocol for halting and restarting 2',3'-dideoxyinosine to minimize certain side effects.

Treatment of human retroviral infections with 2',3'-dideoxyinosine alone

The present invention discloses a sandwich method and a kit for assaying interleukin-2 receptor (IL-2R) in a sample. The method comprises determining reactivity of said sample with a plurality of ligands, each said ligand having binding affinity for a specific site on the receptor, said site being different for each said ligand and distinct from interleukin-2 binding site on the receptor. The invention also discloses a method of detecting such disturbed or abnormal conditions in humans which release soluble IL-2R in the body fluid.

Soluble interleukin-2 receptor as a disease indicator and a method of

Growing community of inventors

Bethesda, MD, United States of America

Robert Yarchoan